160 related articles for article (PubMed ID: 19294384)
1. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.
O'Donnell RT; Pearson D; McKnight HC; Ma YP; Tuscano JM
Cancer Immunol Immunother; 2009 Oct; 58(10):1715-22. PubMed ID: 19294384
[TBL] [Abstract][Full Text] [Related]
2. Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells.
O'Donnell RT; Pearson D; McKnight HC; Ma YP; Tuscano JM
Leuk Res; 2009 Jul; 33(7):964-9. PubMed ID: 19237192
[TBL] [Abstract][Full Text] [Related]
3. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.
O'Donnell RT; Ma Y; McKnight HC; Pearson D; Tuscano JM
Cancer Immunol Immunother; 2009 Dec; 58(12):2051-8. PubMed ID: 19437017
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.
Kong Y; Barisone GA; Abuhay M; O'Donnell RT; Buksh Z; Yousefian F; Tuscano JM
Leuk Res; 2014 Nov; 38(11):1320-6. PubMed ID: 25241275
[TBL] [Abstract][Full Text] [Related]
5. The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
Martin SM; Churchill E; McKnight H; Mahaffey CM; Ma Y; O'Donnell RT; Tuscano JM
J Hematol Oncol; 2011 Dec; 4():49. PubMed ID: 22128838
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
Tuscano JM; O'Donnell RT; Miers LA; Kroger LA; Kukis DL; Lamborn KR; Tedder TF; DeNardo GL
Blood; 2003 May; 101(9):3641-7. PubMed ID: 12511412
[TBL] [Abstract][Full Text] [Related]
7. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.
Abuhay M; Kato J; Tuscano E; Barisone GA; Sidhu RS; O'Donnell RT; Tuscano JM
Cancer Immunol Immunother; 2016 Oct; 65(10):1169-75. PubMed ID: 27506529
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
9. The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone.
Tuscano JM; Ma Y; Martin SM; Kato J; O'Donnell RT
Cancer Immunol Immunother; 2011 Jun; 60(6):771-80. PubMed ID: 21347809
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy of non-Hodgkin's lymphomas (NHL) by anti-CD22 antibody--review].
Lu PP; Meng ZY; Zhou MX; Wang MW; Dou GF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1258-61. PubMed ID: 17204206
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
12. The Protein Tyrosine Phosphatase SHP-1 (PTPN6) but Not CD45 (PTPRC) Is Essential for the Ligand-Mediated Regulation of CD22 in BCR-Ligated B Cells.
Alborzian Deh Sheikh A; Akatsu C; Abdu-Allah HHM; Suganuma Y; Imamura A; Ando H; Takematsu H; Ishida H; Tsubata T
J Immunol; 2021 Jun; 206(11):2544-2551. PubMed ID: 33990399
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).
O'Donnell RT; Martin SM; Ma Y; Zamboni WC; Tuscano JM
Invest New Drugs; 2010 Jun; 28(3):260-7. PubMed ID: 19306119
[TBL] [Abstract][Full Text] [Related]
16. Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation.
Tuscano J; Engel P; Tedder TF; Kehrl JH
Blood; 1996 Jun; 87(11):4723-30. PubMed ID: 8639842
[TBL] [Abstract][Full Text] [Related]
17. Novel binding site for Src homology 2-containing protein-tyrosine phosphatase-1 in CD22 activated by B lymphocyte stimulation with antigen.
Zhu C; Sato M; Yanagisawa T; Fujimoto M; Adachi T; Tsubata T
J Biol Chem; 2008 Jan; 283(3):1653-1659. PubMed ID: 18024433
[TBL] [Abstract][Full Text] [Related]
18. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
19. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy.
Tuscano JM; Kato J; Pearson D; Xiong C; Newell L; Ma Y; Gandara DR; O'Donnell RT
Cancer Res; 2012 Nov; 72(21):5556-65. PubMed ID: 22986740
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma.
Kato J; O'Donnell RT; Abuhay M; Tuscano JM
Oncoimmunology; 2012 Dec; 1(9):1469-1475. PubMed ID: 23264893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
